Hereditary angioedema: A decade of management with stanozolol*

https://doi.org/10.1016/S0091-6749(87)80277-4Get rights and content

Thirty-seven patients with hereditary angioedema, who, without therapy, had attacks of cutaneous angioedema, gastrointestinal colic, and/or upper respiratory symptoms at a frequency and severity sufficient to prompt treatment with an attenuated androgen, have been evaluated for the incidence of side effects and biochemical toxicity during various schedules leading to the minimal effective dose. Stanozolol was administered in a 2 mg daily dose, initially, and after the symptoms and signs were adequately controlled for 2 months at this dose or at 1 mg per day, the drug was administered every other day at 4 mg. Patients who responded adequately to this schedule were administered 2 or 1 mg every other day, and then the interval between doses was gradually increased to 1 week, after which the agent was stopped. Eighteen patients experienced adverse reactions to stanozolol while the minimal effective dose was attained. In each instance the side effect subsided with a reduction in dosage. The most common adverse reactions were biochemical evidence of hepatic dysfunction and, to a lesser extent, hirsutism and menstrual irregularities. Although 21 of 27 patients in an initial study of the minimal effective dose were maintained with daily therapy in 1980, by 1986 this group and 10 additional patients were distributed so that three patients were receiving no daily maintenance, 18 were receiving alternate-day maintenance, and 16 patients were receiving maintenance therapy. Thus, stanozolol appears to be a safe and effective agent for management of hereditary angioedema when patients are continually monitored to define the minimal effective dose or the feasibility of stopping the drug.

References (18)

There are more references available in the full text version of this article.

Cited by (66)

  • US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

    2021, Journal of Allergy and Clinical Immunology: In Practice
  • Prophylactic Therapy for Hereditary Angioedema

    2017, Immunology and Allergy Clinics of North America
  • Critical appraisal of androgen use in hereditary angioedema: A systematic review

    2015, Annals of Allergy, Asthma and Immunology
    Citation Excerpt :

    Two pediatric patients (aged 11 and 14 years) received danazol, 300 mg, day 4 days before and 4 days after dental extraction, with no exacerbation of HAE.45 On the basis of data from prospective studies, the most commonly reported adverse events associated with androgen therapy for HAE include weight gain, menstrual irregularities, virilization, headaches, myalgias or cramps, and mood changes (eg, depression and anxiety) (eTable 2).15,17,20,22–25 In general, more prolonged use and higher doses were associated with an increased risk of adverse events.

  • International consensus on hereditary and acquired angioedema

    2012, Annals of Allergy, Asthma and Immunology
View all citing articles on Scopus
*

Supported by National Institutes of Health Grants AI-22531, AI-23401, HL-36110, AM-35907, and RR-05669.

1

From the Department of Medicine, Harvard Medical School, and the Department of Rheumatology/Immunology, Brigham and Women's Hospital, Boston, Mass.

View full text